Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ximelagatran.

Anirban Choudhury1, Deepak Goyal, Gregory Y H Lip

  • 1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.

Drugs of Today (Barcelona, Spain : 1998)
|March 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International study of Coronary Microvascular Angina (iCorMicA): a registry-based diagnostic study and nested randomized trial.

American heart journal·2026
Same author

Suture-Based Technique for Patellar Osteochondral Fractures Fixation Using an All-Absorbable Implant.

Arthroscopy techniques·2025
Same author

Calcium Challenge - Tackling Rings, Nodules and Plates: How Can We Get More from Intravascular Lithotripsy Technology?

Interventional cardiology (London, England)·2025
Same author

Sclerotherapy of abdominal lymphangioma: An effective treatment modality.

Medical journal, Armed Forces India·2025
Same author

Orbital atherectomy for stent implantation: the ECLIPSE trial.

Lancet (London, England)·2025
Same author

Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2025
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Ximelagatran, an oral direct thrombin inhibitor, shows efficacy comparable to warfarin for preventing thromboembolic events. Its convenient dosing and safety profile may improve anticoagulation use.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Warfarin is the standard for long-term thromboembolism prevention.
  • Antiplatelets are preferred for acute coronary syndromes.
  • Anticoagulant therapy has advanced significantly over 50 years.

Purpose of the Study:

  • Investigate the therapeutic potential of ximelagatran.
  • Evaluate ximelagatran's efficacy and safety in various thromboembolic conditions.
  • Compare ximelagatran to standard anticoagulant treatments.

Main Methods:

  • Clinical studies and double-blind trials were conducted.
  • Efficacy was compared to warfarin and low molecular weight heparin.
  • Safety was assessed, including adverse effects like ALT elevations and bleeding.

Related Experiment Videos

Main Results:

  • Ximelagatran demonstrated comparable efficacy to warfarin and LMWH for VTE prophylaxis.
  • It was comparable to warfarin for stroke prevention in atrial fibrillation.
  • Combined with aspirin, it was more effective than aspirin alone post-myocardial infarction.
  • It showed efficacy in secondary VTE prevention and acute DVT treatment.

Conclusions:

  • Ximelagatran offers a favorable efficacy and safety profile.
  • Its oral, fixed-dose administration without monitoring may increase appropriate anticoagulation use.
  • This could lead to a reduced incidence of thromboembolic events.